文献速递细胞病理与分子病理消化与肝胆胰病理胸部病理

NKX2.2免疫组化在细胞学材料中区分尤文肉瘤与形态学模仿者的诊断效用与陷阱

NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls.
PubMed 文献 · Cancer Cytopathol · 2018-10-30

本研究在107例细针穿刺细胞块中评估NKX2.2免疫组化诊断尤文肉瘤(ES)并区分其形态学模仿者的能力。结果显示NKX2.2对ES诊断敏感度100%、特异度85%,但在小细胞癌(80%)和高分化神经内分泌肿瘤(45%)等模仿者中也有表达,间叶性模仿者中42%阳性。结论认为NKX2.2敏感度高但特异度中等,神经内分泌肿瘤是重要诊断陷阱,需结合免疫组化面板和分子检测综合判断。

要点

  • NKX2.2诊断ES敏感度100%、特异度85%,但神经内分泌肿瘤可阳性表达。
  • 小细胞癌80%、高分化神经内分泌肿瘤45%表达NKX2.2,间叶性模仿者42%阳性。
  • 黑色素瘤、腺样囊性癌和淋巴增殖性肿瘤均不表达NKX2.2。

核心结论

  • NKX2.2是ES的高敏感度但仅中等特异度标志物,神经内分泌肿瘤是显著潜在诊断陷阱。
  • NKX2.2表达应结合合适免疫组化面板(常需确认性分子检测)解读以准确诊断ES。

研究设计与样本

  • 对107例细针穿刺细胞块行NKX2.2免疫组化,对核表达范围和强度半定量评分。
  • 队列包括ES 10例、高分化神经内分泌肿瘤20例、黑色素瘤11例、Merkel细胞癌10例、小细胞癌10例等。

主要发现

  • NKX2.2诊断ES敏感度100%、特异度85%。
  • NKX2.2表达见于部分间叶性和上皮性模仿者,最常见于小细胞癌(80%)和高分化神经内分泌肿瘤(45%)。
  • 间叶性模仿者中42%显示NKX2.2表达。
  • 黑色素瘤、腺样囊性癌和淋巴增殖性肿瘤中NKX2.2染色缺失。

关键数值与推荐

  • ES诊断敏感度100%、特异度85%。
  • 小细胞癌NKX2.2表达率80%,高分化神经内分泌肿瘤45%,间叶性模仿者42%。

临床怎么用

  • NKX2.2可用于细胞学材料中ES的诊断,但需警惕神经内分泌肿瘤等模仿者的阳性表达。
  • 解读NKX2.2结果时应结合完整免疫组化面板,常需分子检测确认ES诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ewing sarcoma (ES) is a round cell sarcoma that can be challenging to diagnose on cytologic material given its significant overlap with numerous mesenchymal, epithelial, and lymphoid cytomorphologic mimics. The objective of this study was to assess the utility of a novel marker, NKX2.2, in the diagnosis of ES in cytologic material and its ability to distinguish ES from its mimics. METHODS: NKX2.2 immunohistochemistry was performed on cell blocks from 107 fine-needle aspirations, and nuclear expression was scored semiquantitatively for extent and intensity. The study cohort included ES (n = 10), well differentiated neuroendocrine tumor (n = 20), melanoma (n = 11), Merkel cell carcinoma (n = 10), small cell carcinoma (n = 10), alveolar rhabdomyosarcoma (n = 2), spindle cell/sclerosing rhabdomyosarcoma (n = 2), synovial sarcoma (n = 12), solitary fibrous tumor (n = 2), chronic lymphocytic leukemia (n = 10), lymphoblastic lymphoma (n = 11), adenoid cystic carcinoma (n = 6), and CIC-rearranged sarcoma (n = 1). RESULTS: NKX2.2 had high sensitivity (100%) and moderate specificity (85%) for the diagnosis of ES in cytologic material. NKX2.2 expression also was present in a subset of mesenchymal and epithelial mimics, and staining was most commonly observed in small cell carcinoma (80%) and well differentiated neuroendocrine tumor (45%). Among mesenchymal mimics, 42% exhibited NKX2.2 expression. NKX2.2 staining was absent in melanoma, adenoid cystic carcinoma, and lymphoproliferative neoplasms. CONCLUSIONS: NKX2.2 is a highly sensitive but only moderately specific marker for ES. Neuroendocrine neoplasms exhibit variable NKX2.2 expression and remain a significant potential diagnostic pitfall. Thus, NKX2.2 expression should be interpreted in the context of an appropriate immunohistochemical panel (and often with confirmatory molecular testing) for the accurate diagnosis of ES.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Russell-Goldman E, Hornick JL, Qian X, et al. NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls. Cancer Cytopathol. 2018. PMID: 30376220. doi:10.1002/cncy.22056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。